Sankala Group’s Vaxcyte PCVX Stock Holding History

Sankala Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Hold	186	–	–	0.01%	383
2026 Q1	$10.1K	Hold	186	–	–	0.01%	379
2025 Q4	$11.5K	Buy	+186	New	+$8.32K	0.01%	370

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Sankala Group's PCVX Position: Q2 2026 in Review

Sankala Group held its Vaxcyte (PCVX) position steady in Q2 2026 at 186 shares worth $11.1K. The position accounts for 0.01% of the portfolio, ranked #383.

Sankala Group first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $11.5K in Q4 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Sankala Group held 186 shares of Vaxcyte worth $11.1K as of Q2 2026.
Sankala Group left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up 0.01% of Sankala Group's portfolio in Q2 2026, its #383 holding.
Sankala Group first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
Sankala Group's Vaxcyte position peaked at $11.5K in Q4 2025.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.